Cephalosporins currently in early clinical trials for the treatment of bacterial infections

Bibliography

• Lodise TP, Low DE. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Drugs 2012;72(11):1473-93
   PubMed Web of Science ®Google Scholar
• Barbour A, Schmidt S, Rand KH, Derendorf H. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2009;34(1):1-7
   PubMed Web of Science ®Google Scholar
• Page MG. Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 2006;6(5):480-5
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U. Resistance drives antibacterial drug development. Curr Opin Pharmacol 2011;11(5):433-8
   PubMed Web of Science ®Google Scholar
• Falagas ME, Karageorgopoulos DE. Extended-spectrum beta-lactamase-producing organisms. J Hosp Infect 2009;73(4):345-54
   PubMed Web of Science ®Google Scholar
• Zapun A, Contreras-Martel C, Vernet T. Penicillin-binding proteins and beta-lactam resistance. FEMS Microbiol Rev 2008;32(2):361-85
   PubMed Web of Science ®Google Scholar
• Wang JF, Chou KC. Metallo-beta-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design. Curr Top Med Chem 2013;13(10):1242-53
   PubMed Web of Science ®Google Scholar
• Nikaido H, Pagès JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol Rev 2012;36(2):340-63
   PubMed Web of Science ®Google Scholar
• Fernández L, Hancock RE. Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 2012;25(4):661-81
   PubMed Web of Science ®Google Scholar
• Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005;352(4):380-91
   PubMed Web of Science ®Google Scholar
• Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother 2010;54(3):969-76
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009;22(1):161-82
   PubMed Web of Science ®Google Scholar
• Patel G1, Bonomo RA. ‘Stormy waters ahead’: global emergence of carbapenemases. Front Microbiol 2013;14(4):48
   Google Scholar
• Lagacé-Wiens P, Walkty A, Karlowsky JA. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 2014;9:13-25
   PubMedGoogle Scholar
• Comparative study of coadministered ceftaroline fosamil and NXL104 vs. intravenous doripenem in adult subjects with complicated urinary tract infections. Available from: http://clinicaltrials.gov/show/NCT01281462
   Google Scholar
• Aktas Z, Kayacan C, Oncul O. In vitro activity of avibactam (NXL104) in combination with beta-lactams against gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2012;39(1):86-9
   PubMed Web of Science ®Google Scholar
• Wagman AS, Moser HE. Carbacephem beta-lactam antibiotics. US20100267686 A1; 2010
   Google Scholar
• Chen M, Zhu S. Cephalosporin compounds comprising a C3 thio-methyl moiety substituted with. N-containing heterocyclic group, and a C7 thiourea acetamido group, their preparations and uses thereof. US20080182836 A1; 2008
   Google Scholar
• Long DD. Cross-linked glycopeptide-cephalosporin antibiotics. US20120214967 A1; 2012
   Google Scholar
• Fatheree PR, Linsell MS, Marquess D, et al. Cross-linked Glycopeptide-cephalosporin antibiotics. US20110224130 A1; 2011
   Google Scholar
• Huang Z. Cephalosporin antibiotic derivant. CN 101245079 B; 2010
   Google Scholar
• Huang Z. Cephalosporin derivatives containing substitutional nitrogen heterocycle. CN101759710 B; 2010
   Google Scholar
• Pendleton JN, Gorman SP, Gilmore BF. Clinical relevance of the ESKAPE pathogens. Expert Rev Anti Infect Ther 2013;11(3):297-308
   PubMed Web of Science ®Google Scholar
• Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67(3):351-68
   PubMed Web of Science ®Google Scholar
• Strateva T, Yordanov D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 2009;58(Pt 9):1133-48
   PubMed Web of Science ®Google Scholar
• Miethke M, Marahiel MA. Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 2007;71(3):413-51
   PubMed Web of Science ®Google Scholar
• Möllmann U, Heinisch L, Bauernfeind A, et al. Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 2009;22(4):615-24
   PubMed Web of Science ®Google Scholar
• Ohi N, Aoki B, Kuroki T, et al. T. Semisynthetic beta-lactam antibiotics. III. Effect on antibacterial activity and COMT-susceptibility of chlorine-introduction into the catechol nucleus of 6-[(R)-2-[3-(3,4-dihydroxybenzoyl)-3-(3-hydroxypropyl)-1-ureido]-2- phenylacetamido]penicillanic acid. J Antibiot (Tokyo) 1987;40(1):22-8
   PubMed Web of Science ®Google Scholar
• Nishitani Y, Yamawaki K, Yakeoka Y, et al. Cephalosporins having catechol group. W02010050468 A1; 2010
   Google Scholar
• Nishitani Y, Aoki T, Sato J, et al. Novel cephem compound having catechol or pseudo-catechol structure. WO2012147773 A1; 2012
   Google Scholar
• Cho YL, Yun JY, Chae SE, et al. Novel cephalosporin derivatives and pharmaceutical compositions thereof. US20130178455 A1; 2013
   Google Scholar
• Sader HS, Castanheira M, Flamm RK, et al. Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. Antimicrob Agents Chemother 2014;58(3):1684-92
   PubMed Web of Science ®Google Scholar
• Castanheira M, Farrell SE, Krause KM, et al. Contemporary diversity of beta-lactamases among Enterobacteriaceae in the nine U.S. census regions and ceftazidime-avibactam activity tested against isolates producing the most prevalent beta-lactamase groups. Antimicrob Agents Chemother 2014;58(2):833-8
   PubMed Web of Science ®Google Scholar
• Mushtaq S, Warner M, Livermore DM. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J Antimicrob Chemother 2010;65(11):2376-81
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/beta-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs 2014;74:31-51
   PubMed Web of Science ®Google Scholar
• Murano K, Yamanaka T, Toda A, et al. Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure. Bioorg Med Chem 2008;16(5):2261-75
   PubMed Web of Science ®Google Scholar
• Toda A, Ohki H, Yamanaka T, et al. Synthesis and SAR of novel parenteral anti-pseudomonal cephalosporins: discovery of FR264205. Bioorg Med Chem Lett 2008;18(17):4849-52
   PubMed Web of Science ®Google Scholar
• Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013;57(4):1577-82
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013;57(12):6305-10
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2010;65(9):1972-4
   PubMed Web of Science ®Google Scholar
• Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007;51(3):826-30
   PubMed Web of Science ®Google Scholar
• Sader H, Rhomberg P, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011;55(5):2390-4
   PubMed Web of Science ®Google Scholar
• VanScoy B, Mendes RE, McCauley J, et al. Pharmacological basis of beta-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 2013;57(12):5924-30
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Dessard C, Roquilly A, et al. 50% effective dose (ED50) determination of CXA-101 (CXA) alone or in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (EC) strains: comparison with ceftazidime (CAZ) and piperacillin/tazobactam (TZP) [abstract F1-2000]. ICAAC Annual Meeting; San Francisco, CA, USA; 2009
   Google Scholar
• Jacqueline C, Dessard C, Batard E, et al. ED50 determination of CXA-101 alone and in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to ESBL-producing Klebsiella pneumoniae (KP) strains: comparison with ceftazidime (CAZ) and piperacillin/tazobactam (TZP) [abstract B-708]. ICAAC Annual Meeting; Boston, MA, USA; 2010
   Google Scholar
• Miller B, Herberget E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in health adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 2012;56(6):3086-91
   PubMed Web of Science ®Google Scholar
• Wooley M, Miller B, Krishna G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane/tazobactam. Antimicrob Agents Chemother 2014;58(4):2249-55
   PubMed Web of Science ®Google Scholar
• Umeh O, Cebrik D, Friedland I. A double-blind, randomized, phase 2 study to compare the safety and efficacy of intravenous CXA-101 (CXA) and intravenous ceftazidime (CTZ) in complicated urinary tract infection (cUTI) [astract L1-361A]. ICAAC Annual Meeting; Boston, MA, USA; 2010
   Google Scholar
• Lucasti Umek O, Cebrik D, Friedland I. A multicenter, double-blind, randomized, phase 2 study to assess safety and efficacy of ceftolozane/tazobactam (TOL/TAZ) plus metronidazole (MTZ) compared to meropenem (MER) in adult patients with complicated intra-abdominal infectious (cIAI) [abstract K-1709]. ICAAC Annual Meeting; Denver, CO, USA; 2013
   Google Scholar
• Boucher H, Talbot G, Benjamin D Jr, et al. 10 x ’20 Progress – development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013;56(12):1682-94
   PubMed Web of Science ®Google Scholar
• Lagacé O, Walkty A, Karlowsky J. Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections. Core Evid 2014;9:13-25
   PubMedGoogle Scholar
• Edeki T, Armstrong J, Li J. Pharmacokinetics of avibactam (AVI) and ceftazidime (CAZ) following separate or combined administration in healthy volunteers [Abstract A-1019]. ICAAC Annual Meeting; Denver, CO, USA; 2013
   Google Scholar
• Riccobene T, Su S, Rank D. Single- and multiple-dose study to determine the safety, tolerability, and pharmacokinetics of ceftaroline fosamil in combination with avibactam healthy subjects. Antimicrob Agents Chemother 2013;57(3):1496-504
   PubMed Web of Science ®Google Scholar
• Das S, Armstrong J, Mathews D, et al. Randomized, placebo-controlled study to assess the impact on QT/QTc interval of supratherapeutic doses of ceftazidime-avibactam or ceftaroline fosamil-avibactam. J Clin Pharmacol 2014;54(3):331-40
   PubMed Web of Science ®Google Scholar
• Cubist Pharmaceutical. Available from: www.cubist.com/products/cxa_201
   Google Scholar
• ClinicalTrials.gov. Safety and efficacy study of ceftolozane/tazobactam to treat ventilated nosocomial pneumonia (ASPECT-NP). Available from: http://clinicaltrials.gov/ct2/show/NCT02070757
   Google Scholar
• ClinicalTrials.gov. Ceftazidime-avibactam compared with doripenem followed by oral therapy for hospitalized adults with complicated UTIs (urinary tract infections). Available from: www.clinicaltrials.gov/ct2/show/NCT01595438
   Google Scholar
• ClinicalTrials.gov. Ceftazidime-avibactam for the treatment of infections due to ceftazidime resistant pathogens. Available from: www.clinicaltrials.gov/ct2/show/NCT01644643
   Google Scholar
• ClinicalTrials.gov. A study comparing ceftazidime-avibactam+metronidazole versus meropenem in adults with complicated intra-abdominal infections. Available from: www.clinicaltrials.gov/ct2/show/NCT01500239
   Google Scholar
• ClinicalTrials.gov. A study comparing ceftazidime-avibactam versus meropenem in hospitalized adults With nosocomial pneumonia. Available from: www.clinicaltrials.gov/ct2/show/NCT01808092
   Google Scholar
• ClinicalTrials.gov. Comparative study of coadministered ceftaroline Fosamil and NXL104 vs. intravenous doripenem in adult subjects with complicated urinary tract infections. Available from: www.clinicaltrials.gov/ct2/show/NCT01281462
   Google Scholar
• Sievert DM, Ricks P, Edwards JR, et al. Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013;34(1):1-14
   PubMed Web of Science ®Google Scholar
• Drees M, Pineles L, Harris AD, Morgan DJ. Variation in definitions and isolation procedures for multidrug-resistant Gram-negative bacteria: a survey of the society for healthcare epidemiology of America research network. Infect Control Hosp Epidemiol 2014;35(4):362-6
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of the safety, tolerability, and efficacy of MK-7655 + imipenem/cilastatin versus imipenem/cilastatin alone to treat complicated intra-abdominal infection [cIAI] (MK-7655-004 AM2). Available from: https://clinicaltrials.gov/ct2/show/NCT01506271
   Google Scholar
• ClinicalTrials.gov. To investigate the safety and tolerability of aztreonam-avibactam (ATM-AVI). Available from: https://clinicaltrials.gov/ct2/show/NCT01689207
   Google Scholar
• Gilbert D, Guidis R, Boucher H, et al. The 10 x ’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010;50:1081-3
   PubMed Web of Science ®Google Scholar
• Pucci MJ, Bush K. Investigational antimicrobial agents of 2013. Clin Microbiol Rev 2013;26(4):792-821
   PubMed Web of Science ®Google Scholar
• Bonnefoy A, Dupuis-Hamelin C, Steier V, et al. In vitro activity of AVE1220A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. J Antimicrob Chemother 2004;54(2):410-17
   PubMed Web of Science ®Google Scholar
• Lagacé-Wiens PR, Tailor F, Simner P, et al. Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases. Antimicrob Agents Chemother 2011;55(5):2434-7
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Warner M, et al. Activities of NXL103 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2011;55(1):390-4
   PubMed Web of Science ®Google Scholar